Alphamab Oncology
Manufacturing · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Xinghu Streetsip Bldg C23 218, Suzhou, J...Website
www.alphamabonc.comRevenue
$85.2 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Alphamab Oncology
Founded in 2008 and headquartered in SuZhou, China, Alphamab Oncology produces and sells drugs. The Company manufactures and sells tumor immunobiology macromolecular targeted drug and other products. Alphamab Oncology provides services worldwide.Explore more
Popular SearchesAlphamab OncologySIC Code 28,283NAICS Code 32,325Show moreAlphamab Oncology Org Chart
QD
Vice President Head of Regulatory Affairs
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alphamab Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Alphamab Oncology
Alphamab Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Alphamab Oncology recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Alphamab Oncology had a recent Job posting/layoffs
Check if Alphamab Oncology has recently received funding, and reach out quickly before it becomes old news!
Check out if Alphamab Oncology is spiking on competitors!
Funding: Get notified immidiatlly once Alphamab Oncology has new funding data
Product Launch: Get notified when Alphamab Oncology launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Alphamab Oncology is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alphamab Oncology is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alphamab Oncology.
Alphamab Oncology financials insights
Gather financial insights about Alphamab Oncology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$100M
2019
Series B
$60M
Alphamab Oncology Tech Stack
A closer look at the technologies used by Alphamab Oncology
See more technologies
Most Recent Scoops
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
Person-Based
Left Company
Executive Move
Funding
Funding
Alphamab Oncology News & Media
Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE
SUZHOU, China, March 13, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a clinical study of JSKN021 for the treatment of advanced malignantAlphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer
SUZHOU, China, March 11, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the appointment of Dr. Hongwei Wang as Chief Technology Officer (CTO). Dr. Wang will be responsible for the company's Process Development and Analytical Development Department, Production Department and Quality Department, and report to Dr. Ting Xu, Chairman and CEO of Alphamab Oncology. Dr. Hongwei Wang is a seasoned expert in biopharmaceutical CMC (Chemistry, Manufacturing, and Controls) developmentStay True to Our Original Aspiration, Forge Ahead into the Future｜Alphamab Oncology 2025 R&D Day Successfully Held
SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- On December 8, 2025, Alphamab Oncology (Stock Code: 9966.HK) successfully held its "Stay True to Our Original Aspiration, Forge Ahead into the Future" 2025 R&D Day in Shanghai. The event focused on the latest advancements in the field of antibody-drug conjugates (ADCs), comprehensively showcasing the company's R&D achievements in bispecific ADCs and dual-payload ADCs. It also shared a highly differentiated and globally competitive product pipeline andAlphamab Oncology Showcases Cutting-edge Breakthroughs and Innovative Achievements at the 16th World ADC San Diego
SUZHOU, China, Nov. 6, 2025 /PRNewswire/ -- The 16th World ADC San Diego, held from November 3–6, 2025, brought together industry leaders in San Diego, USA. Dr. Ting Xu, Founder, Chairman, and CEO of Alphamab Oncology, was invited to deliver a presentation titled "JSKN021: EGFR/HER3 Targeted Dual-payload ADC", showcasing the company's cutting-edge technological breakthroughs and innovative achievements in the ADC field to a global audience. The modularly designed dual-payload ADC platform techno
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alphamab Oncology
Sign Up For FreeTo access detailed company insights
Founded in 2008 and headquartered in SuZhou, China, Alphamab Oncology produces and sells drugs. The Company manufactures and sells tumor immunobiology macromolecular targeted drug and other products. Alphamab Oncology provides services worldwide.... Read More
